文献速递心外重症与机械循环支持

红细胞老化作为持续流左心室辅助装置贫血机制与装置血栓生物标志物

Erythrocyte aging as a mechanism of anemia and a biomarker of device thrombosis in continuous-flow left ventricular assist devices.
PubMed 文献 · J Heart Lung Transplant · 2017-02-09

结果显示CF-LVAD患者红细胞寿命显著缩短,合并血栓者更短,且红细胞寿命检测装置血栓的AUC达0.94。

要点

  • CF-LVAD患者红细胞寿命显著缩短,合并装置血栓者缩短更明显。
  • 红细胞寿命对装置血栓检测具有高敏感性和特异性(AUC=0.94)。
  • CF-LVAD相关贫血主要为红细胞加速老化所致。

核心结论

  • CF-LVAD患者红细胞寿命显著缩短,装置血栓时更明显,贫血主要源于红细胞加速老化。

主要发现

  • 有血栓CF-LVAD患者平均红细胞寿命29.7±14.9天,无血栓者65.0±17.3天(p<0.0001)。
  • 两组CF-LVAD患者红细胞寿命均显著短于正常对照的96.0±24.9天(均p<0.0001)。
  • 红细胞寿命检测装置血栓的ROC曲线AUC=0.94。
  • 所有CF-LVAD患者血红蛋白偏低(11.8±2.0 g/dl),贫血为正色素正细胞性伴网织红细胞计数升高。
  • 红细胞寿命与平均红细胞血红蛋白浓度(r=0.56,p=0.0005)及红细胞分布宽度(r=-0.65,p<0.001)显著相关,与网织红细胞计数无关(r=0.27,p=0.32)。

临床怎么用

  • 红细胞寿命可作为CF-LVAD患者装置血栓的潜在生物标志物。
  • 监测红细胞寿命有助于解释CF-LVAD相关贫血机制。

局限性

  • 需进一步研究确定红细胞寿命能否用于检测亚临床血栓。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Blood trauma caused by continuous-flow left ventricular assist devices (CF-LVADs) has been associated with device thrombosis and anemia. Accurate in vivo quantification of erythrocyte turnover and its contribution to CF-LVAD complications have yet to be elucidated. METHODS: We investigated the age (lifespan) of circulating erythrocytes in subjects with CF-LVAD. Erythrocyte lifespan is a quantitative indicator of in vivo erythrocyte turnover that can be accurately derived from measurement of the exhaled carbon monoxide (CO) level. Sixty non-smoking subjects were prospectively enrolled: 25 had a CF-LVAD without thrombosis; 10 had a CF-LVAD with thrombosis; and 25 were normal controls. End-tidal breath CO levels were measured and used to calculate erythrocyte lifespan. RESULTS: The mean erythrocyte lifespan was significantly shorter in CF-LVAD subjects with (29.7 ± 14.9 days) compared to those without (65.0 ± 17.3 days) device thrombosis (p < 0.0001). The lifespans in these 2 groups were significantly shorter compared with normal controls (96.0 ± 24.9 days, both p < 0.0001). A receiver operator curve demonstrated high sensitivity-specificity for use of erythrocyte lifespan to detect device thrombosis (AUC = 0.94). In addition, all CF-LVAD subjects had low hemoglobin (11.8 ± 2.0 g/dl), and their anemia was normochromic normocytic with elevated mean reticulocyte counts. Erythrocyte lifespan correlated significantly with mean corpuscular hemoglobin concentration (r = 0.56, p = 0.0005) and red cell distribution width (r = -0.65, p < 0.001), but not with reticulocyte count (r = 0.27, p = 0.32). CONCLUSIONS: Erythrocyte lifespan is substantially reduced in subjects with a CF-LVAD, which was more pronounced in the presence of device thrombosis. The etiology of anemia in CF-LVAD was primarily due to accelerated erythrocyte aging. Further studies are needed to determine whether erythrocyte lifespan could provide a practical means of detecting subtle pre-clinical thrombosis.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Taimeh Z, Koene RJ, Furne J, et al. Erythrocyte aging as a mechanism of anemia and a biomarker of device thrombosis in continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2017. PMID: 28396088. doi:10.1016/j.healun.2017.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。